SCHEMBL672634

SCHEMBL672634

O=C(O)c1c(Sc2cccc(Br)c2)c2ccc(Cl)cc2n1Cc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
CYP3A4 P08684 1/20 0.64
MAPT P10636 1/20 0.64
ALOX15 P16050 1/20 0.64
TSHR P16473 1/20 0.64
ALOX12 P18054 1/20 0.64
PPARG P37231 1/20 0.64
RECQL P46063 1/20 0.64
BLM P54132 1/20 0.64
HSD17B10 Q99714 1/20 0.64
EDNRB P24530 12/20 0.58
EDNRA P25101 12/20 0.58
ENPP2 Q13822 2/20 0.47
AKR1B1 P15121 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
HDAC6 Q9UBN7 1/20 0.43
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL671128 0.88 EDNRB (0.50) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL21465466 0.87 MEN1 (0.83) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL15024256 0.84 PTGDR2 (0.52) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL29465029 0.81 MEN1 (0.93) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL21465521 0.81 MEN1 (0.93) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL21465481 0.80 MAPT (0.85) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL6709652 0.78 MEN1 (1.00) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL670612 0.77 ENPP2 (0.73) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL23759979 0.77 MEN1 (0.73) MEN1KMT2ACYP3A4MAPTALOX15
SCHEMBL670432 0.76 ENPP2 (0.61) MEN1KMT2ACYP3A4MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11690824-B2 Antibacterial compounds THE GENERAL HOSPITAL CORPORATION (US) 2023-07-04 US disclosed
US-11690824-B2 Antibacterial compounds THE GENERAL HOSPITAL CORPORATION (US) 2023-07-04 US disclosed
US-9849109-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2017-12-26 US disclosed
US-9849109-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2017-12-26 US disclosed
US-9849109-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2017-12-26 US disclosed
EP-2606031-B1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS INC (US) 2017-09-27 EP disclosed
EP-2606031-B1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS INC (US) 2017-09-27 EP disclosed
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2015-06-18 US disclosed
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2015-06-18 US disclosed
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2015-06-18 US disclosed
US-9000025-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2015-04-07 US disclosed
US-9000025-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2015-04-07 US disclosed
US-9000025-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2015-04-07 US disclosed
EP-2606031-A2 AUTOTAXIN INHIBITORS AND USES THEREOF Amira Pharmaceuticals, Inc. (US) 2013-06-26 EP disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 US disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 US disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 US disclosed
WO-2012024620-A2 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2012-02-23 WO disclosed
WO-2012024620-A2 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, SERPINE1 MEN1 813/4885KMT2A 3249/4885CYP3A4 4638/4885
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, SERPINE1 MEN1 813/4885KMT2A 3249/4885CYP3A4 4638/4885
US-11690824-B2 Antibacterial compounds MRPL21, SPOUT1, BAX MEN1 4156/4885KMT2A 4827/4885CYP3A4 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.